Back to top

Analyst Blog

XOMA Corporation (XOMA - Snapshot Report) recently announced that its partner, Les Laboratoires Servier, a French pharmaceutical company, has initiated an independent proof-of-concept (POC) clinical program on gevokizumab. The POC program will be evaluating the safety and efficacy of gevokizumab in several therapeutics areas.

XOMA has collaborated with privately held Servier for the development of gevokizumab, an interleukin-1 beta (IL-1 beta) modulating antibody. XOMA and Servier are evaluating the use of gevokizumab in a number of indications including non-infectious uveitis (NIU) involving the intermediate and/or posterior portion of the eye and Behçet’s uveitis. The potential of the candidate to improve symptoms of pain, physical function and other abnormalities in patients suffering from erosive osteoarthritis of the hand is also being evaluated.

The first study under the POC program on gevokizumab will be in patients suffering from polymyositis/dermatomyositis.

We note that XOMA had initiated a similar POC program on gevokizumab in Nov 2011 for indications like moderate-to-severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the hand, and non-anterior scleritis.

In Jan 2013, XOMA reported preliminary top-line data from a phase II POC study in the inflammatory acne indication. Preliminary results from the study showed that the 0.6mg/kg dose of gevokizumab demonstrated a significant reduction of 19 in mean inflammatory lesion count compared to a reduction of 13 in patients under the placebo group on day 42. The difference was maintained throughout the study.

 XOMA recently initiated a pilot study to evaluate the use of gevokizumab in patients suffering from acute inflammatory pyoderma gangrenosum (PG). XOMA intends to enrol up to 8 patients suffering from acute inflammatory PG for the study. Their disease is characterized by recently developed active ulcers apart from ulcer-related pain.

Gevokizumab is the lead candidate at XOMA. The company has progressed well so far with the candidate. We expect investor focus to stay on gevokizumab going forward.

XOMA carries a Zacks Rank #3 (Hold). Companies that currently look attractive include Santarus, Inc. , Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals (SLXP - Analyst Report). All the three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%